Ivax Pharmaceuticals, Inc., will distribute in the United States, through an exclusive licensing agreement derived from another company’s recently approved ANDA, levothyroxine sodium tablets USP in .025, .05, .075, .088, .1, .112, .125, .15, .175, .2 and .3 mg dosage strengths.
Levothyroxine sodium tablets USP are the generic equivalent of Synthroid, a naturally occurring thyroid hormone used to treat low thyroid levels, which is marketed by Abbott Laboratories. According to IMS data, US sales for Synthroid were approximately $677 million during the twelve months ending June 30, 2005.